The estimated Net Worth of John Oyler is at least $417 Milion dollars as of 6 July 2021. Mr. Oyler owns over 123,821 units of BeiGene Ltd stock worth over $63,345 and over the last 9 years he sold BGNE stock worth over $403,243,973. In addition, he makes $13,899,000 as Co-Founder, Executive Chairman of the Board oraz Chief Executive Officer at BeiGene Ltd.
Sign up
Mr. Oyler BGNE stock SEC Form 4 insiders trading
John has made over 48 trades of the BeiGene Ltd stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 2,789 units of BGNE stock worth $445,069 on 24 June 2024.
The largest trade he's ever made was selling 411,838 units of BeiGene Ltd stock on 14 September 2021 worth over $33,787,190. On average, John trades about 52,803 units every 44 days since 2016. As of 6 July 2021 he still owns at least 300 units of BeiGene Ltd stock.
You can see the complete history of Mr. Oyler stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Oyler biography
John Victor Oyler serves as Co-Founder, Executive Chairman of the Board, Chief Executive Officer of the Company. 2005 to 2009, Mr. Oyler served as President and Chief Executive Officer of BioDuro, LLC, a drug discovery outsourcing company, which was acquired by Pharmaceutical Product Development Inc. From 2002 to 2004, Mr. Oyler served as Chief Executive Officer of Galenea Corp., a biopharmaceutical company dedicated to the discovery of novel therapies for central nervous system diseases, which initially were developed at Massachusetts Institute of Technology. From 1998 to 2002, Mr. Oyler was a Founder and the President of Telephia, Inc. which was bought by The Nielsen Company in 2007. From 1997 to 1998, Mr. Oyler served as Co-Chief Executive Officer of Genta Incorporated, an oncologyfocused biopharmaceutical company that was listed on the NASDAQ. Mr. Oyler began his career as a management consultant at McKinsey & Company. Mr. Oyler received his B.S. from the Massachusetts Institute of Technology in June 1990 and an MBA from Stanford University in January 1996. Mr. Oyler’s qualifications to serve on our Board of Directors include his extensive leadership, executive, managerial, business and pharmaceutical and biotechnology company experience, along with his years of industry experience in the development and commercialization of pharmaceutical products.
What is the salary of John Oyler?
As the Co-Founder, Executive Chairman of the Board oraz Chief Executive Officer of BeiGene Ltd, the total compensation of John Oyler at BeiGene Ltd is $13,899,000. There are no executives at BeiGene Ltd getting paid more.
How old is John Oyler?
John Oyler is 52, he's been the Co-Founder, Executive Chairman of the Board oraz Chief Executive Officer of BeiGene Ltd since 2010. There are 11 older and 10 younger executives at BeiGene Ltd. The oldest executive at BeiGene Ltd is Donald Glazer, 75, who is the Non-Executive Independent Director.
What's John Oyler's mailing address?
John's mailing address filed with the SEC is C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN, E9, KY1-1108.
Insiders trading at BeiGene Ltd
Over the last 9 years, insiders at BeiGene Ltd have traded over $1,899,158,980 worth of BeiGene Ltd stock and bought 23,241,738 units worth $1,040,248,444 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Investment Management, Ltd.... oraz Bros. Advisors Lp Baker Bro.... On average, BeiGene Ltd executives and independent directors trade stock every 13 days with the average trade being worth of $33,382,815. The most recent stock trade was executed by Xiaobin Wu on 3 September 2024, trading 5,556 units of BGNE stock currently worth $1,053,695.
What does BeiGene Ltd do?
BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.
What does BeiGene Ltd's logo look like?
Complete history of Mr. Oyler stock trades at BeiGene Ltd
BeiGene Ltd executives and stock owners
BeiGene Ltd executives and other stock owners filed with the SEC include:
-
John Oyler,
Co-Founder, Executive Chairman of the Board, Chief Executive Officer -
Xiaodong Wang,
Co-Founder, Non-Executive Director -
Dr. Xiaodong Wang Ph.D.,
Co-Founder, Chairman of the Scientific Advisory Board & Non-Exec. Director -
John V. Oyler,
Co-Founder, Exec. Chairman & CEO -
Dr. Xiaobin Wu Ph.D.,
Pres, COO & GM of China -
Wang Lai,
Global Head of R&D -
Dr. Edna Huang M.D.,
Chief Medical Officer of Hematology -
Dr. Jane Edna Huang M.D.,
Chief Medical Officer of Hematology -
Dr. Heng Liang,
CFO & Chief Strategy Officer -
Thomas Malley,
Non-Executive Independent Director -
Qingqing YI,
Non-Executive Independent Director -
Timothy Chen,
Non-Executive Independent Director -
Jing-Shyh Su,
Non-Executive Independent Director -
Donald Glazer,
Non-Executive Independent Director -
Ranjeev Krishana,
Non-Executive Independent Director -
Michael Goller,
Non-Executive Independent Director -
Corazon Sanders,
Non-Executive Independent Director -
Anthony Hooper,
Non-Executive Director -
Hing Ling Chau,
Company Secretary -
Jane Huang,
Chief Medical Officer, Hematology -
Xiaobin Wu,
General Manager - China, President -
Kevin C. Mannix,
Sr. VP of Investor Relations. -
Mi Zhou,
Sr. Director of Investor Relations -
Julia Wang,
CFO & Principal Accounting Officer -
Diana Lee Francis,
VP and Global Head of Quality & Regulatory Compliance -
Scott Samuels,
Sr. VP & Gen. Counsel -
Craig West CFA,
Sr. Director of Investor Relations -
Michael Garvey,
Global Head of Technical Operations -
Daniel Maller,
VP of Fin. & Accounting -
Jianxin Yang,
Sr. VP, Head of Clinical Dev. -
Amy C. Peterson,
CMO, Immuno-oncology -
Ji Li,
EVP and Gl. Head of Bus. Dev. -
Investment Management, Ltd....,
10% owner -
Rui Rong Yuan,
Chief Medical Officer -
Ke Tang,
Director -
Bros. Advisors Lp Baker Bro...,
-
Biotech Investment Ltd Cpe ...,
-
Wendy Xiaojun Yan,
Sr. VP, Head of Reg. Affairs -
& Co., Inc.Merck Sharp & Do...,
-
Chan Henry Lee,
SVP, General Counsel -
Bros. Advisors Lp14159, L.P...,
-
Bros. Advisors Lp667, L.P.B...,
-
Howard Liang,
CFO & Chief Strategy Officer -
Inc Amgen,
10% owner -
Lai Wang,
Global Head of R&D -
Olivier Brandicourt,
Director -
Julia Aijun Wang,
Chief Financial Officer -
Margaret Dugan,
Director -
Advisors, Ltd.Hillhouse Inv...,
-
Bros. Advisors Lp667, L.P.B...,
-
Titus B. Ball,
Principal Accounting Officer -
Aaron Rosenberg,
Chief Financial Officer